{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:34:26Z","timestamp":1791581666987,"version":"4.3.4"},"reference-count":200,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.gastro.2026.02.010","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:30:17Z","timestamp":1771590617000},"page":"1152-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut\u2013Brain Interaction"],"prefix":"10.1053","volume":"170","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-7514","authenticated-orcid":false,"given":"Michael","family":"Camilleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley","family":"Greenwood-Van Meerveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo A.","family":"Izzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.02.010_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.509681","article-title":"Animal models for functional gastrointestinal disorders","volume":"11","author":"Accarie","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1053\/j.gastro.2026.02.010_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1099800403005001006","article-title":"Impact of sex and gender on irritable bowel syndrome","volume":"5","author":"Heitkemper","year":"2003","journal-title":"Biol Res Nurs"},{"key":"10.1053\/j.gastro.2026.02.010_bib3","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0016-5085(03)00400-1","article-title":"Sex-related differences in IBS patients: central processing of visceral stimuli","volume":"124","author":"Naliboff","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jpain.2012.11.008","article-title":"Sexually dimorphic effects of unpredictable early life adversity on visceral pain behavior in a rodent model","volume":"14","author":"Chaloner","year":"2013","journal-title":"J Pain"},{"key":"10.1053\/j.gastro.2026.02.010_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/nmo.12472","article-title":"Gender specific effects of neonatal limited nesting on viscerosomatic sensitivity and anxiety-like behavior in adult rats","volume":"27","author":"Prusator","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13293-016-0082-x","article-title":"Sex-related differences in pain behaviors following three early life stress paradigms","volume":"7","author":"Prusator","year":"2016","journal-title":"Biol Sex Differ"},{"key":"10.1053\/j.gastro.2026.02.010_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cgh.2011.12.018","article-title":"Association between early adverse life events and irritable bowel syndrome","volume":"10","author":"Bradford","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib8","doi-asserted-by":"crossref","first-page":"G885","DOI":"10.1152\/ajpgi.00463.2014","article-title":"Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges","volume":"308","author":"Greenwood-Van Meerveld","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13776","article-title":"Critical evaluation of animal models of visceral pain for therapeutics development: a focus on irritable bowel syndrome","volume":"32","author":"Johnson","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib10","doi-asserted-by":"crossref","first-page":"G42","DOI":"10.1152\/ajpgi.00500.2004","article-title":"Repeated exposure to water avoidance stress in rats: a new model for sustained visceral hyperalgesia","volume":"289","author":"Bradesi","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95916-5","article-title":"Juvenile social defeat stress exposure favors in later onset of irritable bowel syndrome-like symptoms in male mice","volume":"11","author":"Matsumoto","year":"2021","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2026.02.010_bib12","doi-asserted-by":"crossref","first-page":"G307","DOI":"10.1152\/ajpgi.00240.2001","article-title":"Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat","volume":"282","author":"Coutinho","year":"2002","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1365-2982.2007.00955.x","article-title":"Long-term colonic hypersensitivity in adult rats induced by neonatal unpredictable vs predictable shock","volume":"19","author":"Tyler","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib14","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/gast.2000.19576","article-title":"A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development","volume":"119","author":"Al-Chaer","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib15","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0031-9384(99)00254-1","article-title":"Evidence for visceral hypersensitivity in high-anxiety rats","volume":"69","author":"Gunter","year":"2000","journal-title":"Physiol Behav"},{"key":"10.1053\/j.gastro.2026.02.010_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00210-007-0195-1","article-title":"Characterisation of colonic accommodation in Wistar Kyoto rats with impaired gastric accommodation","volume":"376","author":"Martinez","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1053\/j.gastro.2026.02.010_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13614","article-title":"Colonic hypersensitivity and low-grade inflammation in a spontaneous animal model for functional gastrointestinal disorders","volume":"31","author":"Meleine","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib18","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1365-2982.2007.00951.x","article-title":"Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity","volume":"19","author":"Trimble","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib19","doi-asserted-by":"crossref","first-page":"eaaf6397","DOI":"10.1126\/scitranslmed.aaf6397","article-title":"Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice","volume":"9","author":"De Palma","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0006-8993(88)91555-7","article-title":"Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat","volume":"450","author":"Ness","year":"1988","journal-title":"Brain Res"},{"key":"10.1053\/j.gastro.2026.02.010_bib21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2019.04.034","article-title":"Extrinsic primary afferent neurons link visceral pain to colon motility through a spinal reflex in mice","volume":"157","author":"Smith-Edwards","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib22","article-title":"Assessment of gastric emptying in non-obese diabetic mice using a [13C]-octanoic acid breath test","volume":"73","author":"Creedon","year":"2013","journal-title":"J Vis Exp"},{"key":"10.1053\/j.gastro.2026.02.010_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1538\/expanim.19-0030","article-title":"Development of a quantitative method for evaluating small intestinal motility using ultrasonography in mice","volume":"68","author":"Kishi","year":"2019","journal-title":"Exp Anim"},{"key":"10.1053\/j.gastro.2026.02.010_bib24","doi-asserted-by":"crossref","first-page":"755","DOI":"10.9738\/INTSURG-D-14-00078.1","article-title":"New telemetry device for the measurement of gastrointestinal motility in rats and comparison with standard equipment","volume":"100","author":"Meile","year":"2015","journal-title":"Int Surg"},{"key":"10.1053\/j.gastro.2026.02.010_bib25","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.3389\/fphys.2018.01962","article-title":"Investigating gut permeability in animal models of disease","volume":"9","author":"Gonzalez-Gonzalez","year":"2018","journal-title":"Front Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1748-1716.1951.tb00800.x","article-title":"Active transport of sodium as the source of electric current in the short-circuited isolated frog skin","volume":"23","author":"Ussing","year":"1951","journal-title":"Acta Physiol Scand"},{"key":"10.1053\/j.gastro.2026.02.010_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12876-019-1002-4","article-title":"The Ussing chamber system for measuring intestinal permeability in health and disease","volume":"19","author":"Thomson","year":"2019","journal-title":"BMC Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib28","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1136\/gutjnl-2023-330542","article-title":"Abnormal gastrointestinal motility is a major factor in explaining symptoms and a potential therapeutic target in patients with disorders of gut-brain interaction","volume":"72","author":"Camilleri","year":"2023","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib29","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1111\/j.1572-0241.2000.03195.x","article-title":"Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms","volume":"95","author":"Bonapace","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib30","first-page":"277","article-title":"Segmental colonic transit after oral 67Ga-citrate in healthy subjects and those with chronic idiopathic constipation","volume":"40","author":"Bartholomeusz","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib31","first-page":"1807","article-title":"Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets","volume":"38","author":"Burton","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2982.2009.01441.x","article-title":"Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions","volume":"22","author":"Deiteren","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13451","article-title":"Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system","volume":"31","author":"Mark","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib34","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13734","article-title":"Normative values for region-specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D-Transit electromagnet tracking system: influence of age, gender, and body mass index","volume":"32","author":"Nandhra","year":"2020","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF01296258","article-title":"Role of loperamide and placebo in management of irritable bowel syndrome (IBS)","volume":"29","author":"Cann","year":"1984","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/apt.13351","article-title":"Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders","volume":"42","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2982.2003.00389.x","article-title":"Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials","volume":"15","author":"Cremonini","year":"2003","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib39","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1046\/j.1365-2036.2002.01272.x","article-title":"Prucalopride, a systemic enterokinetic, for the treatment of constipation","volume":"16","author":"Emmanuel","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/gast.2001.21166","article-title":"Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder","volume":"120","author":"Bouras","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","article-title":"Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome","volume":"133","author":"Andresen","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib42","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","article-title":"A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation","volume":"107","author":"Rao","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13492","article-title":"Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation","volume":"31","author":"Farmer","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea","volume":"329","author":"von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib46","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14040","article-title":"High-resolution manometry reveals different effect of polyethylene glycol, bisacodyl, and prucalopride on colonic motility in healthy subjects: an acute, open label, randomized, crossover, reader-blinded study with potential clinical implications","volume":"33","author":"Corsetti","year":"2021","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2982.2010.01651.x","article-title":"Anatomical registration and three-dimensional visualization of low and high-resolution pan-colonic manometry recordings","volume":"23","author":"Davidson","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib48","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11517-021-02316-y","article-title":"ManoMap: an automated system for characterization of colonic propagating contractions recorded by high-resolution manometry","volume":"59","author":"Paskaranandavadivel","year":"2021","journal-title":"Med Biol Eng Comput"},{"key":"10.1053\/j.gastro.2026.02.010_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14178","article-title":"High-resolution impedance manometry characterizes the functional role of distal colonic motility in gas transit","volume":"34","author":"Heitmann","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib50","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1136\/gut.2010.213108","article-title":"The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome","volume":"59","author":"Klooker","year":"2010","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0304-3959(00)00282-7","article-title":"Irritable bowel syndrome patients show altered sensitivity to exogenous opioids","volume":"87","author":"Lembo","year":"2000","journal-title":"Pain"},{"key":"10.1053\/j.gastro.2026.02.010_bib52","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2036.2003.01449.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects","volume":"17","author":"Coffin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib53","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s00261-015-0475-z","article-title":"A novel semi-automatic segmentation method for volumetric assessment of the colon based on magnetic resonance imaging","volume":"40","author":"Sandberg","year":"2015","journal-title":"Abdom Imaging"},{"key":"10.1053\/j.gastro.2026.02.010_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.14374","article-title":"Colonic volume in patients with functional constipation or irritable bowel syndrome determined by magnetic resonance imaging","volume":"34","author":"Klinge","year":"2022","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib55","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/apt.16812","article-title":"Gut-brain axis dysfunction underlies FODMAP-induced symptom generation in irritable bowel syndrome","volume":"55","author":"Wu","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296311","article-title":"Colon length in pediatric health and constipation measured using magnetic resonance imaging and three dimensional skeletonization","volume":"19","author":"Sharif","year":"2024","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2026.02.010_bib57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2016.11.013","article-title":"Rectal gas volume measured by computerized tomography identifies evacuation disorders in patients with constipation","volume":"15","author":"Park","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib58","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1016\/j.cgh.2019.04.039","article-title":"Spatial patterns from high-resolution electrogastrography correlate with severity of symptoms in patients with functional dyspepsia and gastroparesis","volume":"17","author":"Gharibans","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.14309\/ajg.0000000000002528","article-title":"Gastric Alimetry(R) expands patient phenotyping in gastroduodenal disorders compared to gastric emptying scintigraphy","volume":"119","author":"Wang","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib60","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-018-0038-z","article-title":"Gastroparesis","volume":"4","author":"Camilleri","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1053\/j.gastro.2026.02.010_bib61","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1016\/j.cgh.2022.05.022","article-title":"Progress in gastroparesis - a narrative review of the work of the Gastroparesis Clinical Research Consortium","volume":"20","author":"Pasricha","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib62","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1053\/j.gastro.2021.02.042","article-title":"Gastroparesis: a dead-end street after all?","volume":"160","author":"Tack","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib63","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1159\/000007687","article-title":"Prokinetics in patients with gastroparesis: a systematic analysis","volume":"60","author":"Sturm","year":"1999","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2026.02.010_bib64","first-page":"259","article-title":"Oral erythromycin and symptomatic relief of gastroparesis: a systematic review","volume":"98","author":"Maganti","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib65","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.7863\/ultra.15.04086","article-title":"Validation of a novel 3-dimensional sonographic method for assessing gastric accommodation in healthy adults","volume":"35","author":"Buisman","year":"2016","journal-title":"J Ultrasound Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2982.2002.00326.x","article-title":"A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health","volume":"14","author":"Chial","year":"2002","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/gut.2003.035279","article-title":"Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying","volume":"54","author":"Arts","year":"2005","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib68","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2036.2011.04775.x","article-title":"Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study","volume":"34","author":"Braak","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib69","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.14309\/ajg.0000000000001242","article-title":"Nutrient drinking test as biomarker in functional dyspepsia","volume":"116","author":"Scarpellini","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2982.2011.01676.x","article-title":"Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation","volume":"23","author":"Janssen","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib71","first-page":"1155","article-title":"Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals","volume":"45","author":"Simonian","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib72","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1136\/gut.51.6.781","article-title":"SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography","volume":"51","author":"Bouras","year":"2002","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib73","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","article-title":"Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales","volume":"19","author":"Sistonen","year":"2009","journal-title":"Pharmacogenet Genomics"},{"key":"10.1053\/j.gastro.2026.02.010_bib74","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1053\/j.gastro.2005.08.062","article-title":"Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders","volume":"130","author":"Camilleri","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib75","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2014.01.050","article-title":"Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies","volume":"146","author":"Shanahan","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib76","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1053\/j.gastro.2014.02.037","article-title":"Brain-gut microbiome interactions and functional bowel disorders","volume":"146","author":"Mayer","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.tips.2014.02.001","article-title":"Insights into drug discovery from natural medicines using reverse pharmacokinetics","volume":"35","author":"Hao","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib78","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/nmo.12384","article-title":"Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials","volume":"26","author":"Cremonini","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/138920013804545124","article-title":"Why we need proper PBPK models to examine intestine and liver oral drug absorption","volume":"14","author":"Chow","year":"2013","journal-title":"Curr Drug Metab"},{"key":"10.1053\/j.gastro.2026.02.010_bib80","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2014.03.001","article-title":"Ligand-mediated active targeting for enhanced oral absorption","volume":"19","author":"Zhang","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1053\/j.gastro.2026.02.010_bib81","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7150\/ntno.62213","article-title":"Novel protocols for scalable production of high quality purified small extracellular vesicles from bovine milk","volume":"5","author":"Marsh","year":"2021","journal-title":"Nanotheranostics"},{"key":"10.1053\/j.gastro.2026.02.010_bib82","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.7150\/thno.73650","article-title":"Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis","volume":"12","author":"Gao","year":"2022","journal-title":"Theranostics"},{"key":"10.1053\/j.gastro.2026.02.010_bib83","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002280100290","article-title":"Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus","volume":"57","author":"De Ponti","year":"2001","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2026.02.010_bib84","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/bmj.325.7364.592","article-title":"Alosetron: a case study in regulatory capture, or a victory for patients' rights?","volume":"325","author":"Moynihan","year":"2002","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2026.02.010_bib85","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.cgh.2017.08.006","article-title":"Risk of pancreatitis following treatment of irritable bowel syndrome with eluxadoline","volume":"16","author":"Gawron","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib86","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/apt.16816","article-title":"Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome","volume":"55","author":"Goodoory","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib87","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200225040-00004","article-title":"Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview","volume":"25","author":"De Ponti","year":"2002","journal-title":"Drug Saf"},{"key":"10.1053\/j.gastro.2026.02.010_bib88","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0009-9236(98)90040-6","article-title":"10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes","volume":"63","author":"Dalen","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib89","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1517\/phgs.4.5.583.23789","article-title":"Pharmacogenetics of monoamine transporters","volume":"4","author":"Glatt","year":"2003","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.gastro.2026.02.010_bib90","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1053\/gast.2002.34780","article-title":"Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome","volume":"123","author":"Camilleri","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib91","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMra020995","article-title":"Chronic constipation","volume":"349","author":"Lembo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles","volume":"128","author":"O'Mahony","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib93","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1365-2036.2004.02267.x","article-title":"Meta-analysis: the treatment of irritable bowel syndrome","volume":"20","author":"Lesbros-Pantoflickova","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib94","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1476-5381.1979.tb16089.x","article-title":"Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones: effects of fluoxetine (Lilly 110140) and chlorimipramine","volume":"66","author":"Gershon","year":"1979","journal-title":"Br J Pharmacol"},{"key":"10.1053\/j.gastro.2026.02.010_bib95","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/gut.35.4.496","article-title":"5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake","volume":"35","author":"Gorard","year":"1994","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.cgh.2015.09.043","article-title":"Efficacy of mirtazapine in patients with functional dyspepsia and weight loss","volume":"14","author":"Tack","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib97","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/gut.2003.035568","article-title":"Pharmacology of serotonin: what a clinician should know","volume":"53","author":"De Ponti","year":"2004","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib98","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/gut.44.5.682","article-title":"Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans","volume":"44","author":"Bouras","year":"1999","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib99","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1365-2036.1999.00629.x","article-title":"Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers","volume":"13","author":"Poen","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib100","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1046\/j.1365-2036.2001.01103.x","article-title":"Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects","volume":"15","author":"Degen","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib101","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5056\/jnm.2013.19.4.495","article-title":"Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study","volume":"19","author":"Lim","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib102","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00535-013-0876-0","article-title":"Effects of mosapride on esophageal motor activity and esophagogastric junction compliance in healthy volunteers","volume":"49","author":"Fukazawa","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib103","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10620-012-2430-y","article-title":"Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry","volume":"58","author":"Cho","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib104","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1440-1746.2011.06949.x","article-title":"Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS)","volume":"27","author":"Hongo","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib105","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1046\/j.1365-2036.2003.01775.x","article-title":"Influence of tegaserod on proximal gastric tone and on the perception of gastric distension","volume":"18","author":"Tack","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib106","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1365-2036.2004.01867.x","article-title":"Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics","volume":"19","author":"Tonini","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib107","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.3748\/wjg.v18.i48.7371","article-title":"Itopride therapy for functional dyspepsia: a meta-analysis","volume":"18","author":"Huang","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib108","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gut.2007.132449","article-title":"Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials","volume":"57","author":"Talley","year":"2008","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib109","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMoa052639","article-title":"A placebo-controlled trial of itopride in functional dyspepsia","volume":"354","author":"Holtmann","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib110","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7654947","article-title":"A combination of peppermint oil and caraway oil for the treatment of functional dyspepsia: a systematic review and meta-analysis","volume":"2019","author":"Li","year":"2019","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib111","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2019.1673365","article-title":"Drugs under development for the treatment of functional dyspepsia and related disorders","volume":"28","author":"Tack","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1053\/j.gastro.2026.02.010_bib112","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","article-title":"A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia","volume":"61","author":"Matsueda","year":"2012","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib113","doi-asserted-by":"crossref","first-page":"618-e173","DOI":"10.1111\/j.1365-2982.2009.01449.x","article-title":"Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage","volume":"22","author":"Matsueda","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1365-2982.2009.01261.x","article-title":"A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia","volume":"21","author":"Tack","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib115","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13284","article-title":"Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)-results from the European phase 3 open-label safety trial","volume":"30","author":"Tack","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib116","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/apt.16588","article-title":"Randomised clinical trial: the effects of pregabalin vs placebo on functional dyspepsia","volume":"54","author":"Kotikula","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib117","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(03)12392-6","article-title":"Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency","volume":"361","author":"Chan","year":"2003","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.02.010_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2011.01766.x","article-title":"A placebo-controlled trial of an oral capsaicin load in patients with functional dyspepsia","volume":"23","author":"Fuhrer","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib119","first-page":"259","article-title":"Capsaicin receptor as target of calcitonin gene-related peptide in the gut","volume":"68","author":"Evangelista","year":"2014","journal-title":"Prog Drug Res"},{"key":"10.1053\/j.gastro.2026.02.010_bib120","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/nmo.12291","article-title":"Dysfunctional endogenous pain modulation in patients with functional dyspepsia","volume":"26","author":"Wilder-Smith","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib121","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2036.2002.01280.x","article-title":"The treatment of functional dyspepsia with red pepper","volume":"16","author":"Bortolotti","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib122","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/lipd.12341","article-title":"2-Arachidonoyl glycerol suppresses gastric emptying via the cannabinoid receptor 1-cholecystokinin signaling pathway in mice","volume":"57","author":"Ochiai","year":"2022","journal-title":"Lipids"},{"key":"10.1053\/j.gastro.2026.02.010_bib123","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","article-title":"Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo","volume":"91","author":"Frytak","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib124","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1046\/j.1365-2036.1999.00441.x","article-title":"Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study","volume":"13","author":"McCallum","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib125","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10620-019-05963-2","article-title":"Marijuana use in patients with symptoms of gastroparesis: prevalence, patient characteristics, and perceived benefit","volume":"65","author":"Parkman","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib126","doi-asserted-by":"crossref","first-page":"945","DOI":"10.14309\/ajg.0000000000000181","article-title":"Cannabinoid use in patients with gastroparesis and related disorders: prevalence and benefit","volume":"114","author":"Jehangir","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib127","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.14309\/ajg.0000000000001805","article-title":"Cannabidiol for functional dyspepsia with normal gastric emptying: a randomized controlled trial","volume":"117","author":"Atieh","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib128","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1089\/can.2020.0087","article-title":"Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: a placebo-controlled crossover exploratory intervention study with symptom-driven dosing","volume":"7","author":"van Orten-Luiten","year":"2022","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1053\/j.gastro.2026.02.010_bib129","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jcmgh.2020.10.001","article-title":"Impaired duodenal palmitoylethanolamide release underlies acid-induced mast cell activation in functional dyspepsia","volume":"11","author":"Sarnelli","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib130","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13304","article-title":"Micro-inflammation in functional dyspepsia: a systematic review and meta-analysis","volume":"30","author":"Du","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib131","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.cgh.2022.01.014","article-title":"Duodenal eosinophils and mast cells in functional dyspepsia: a systematic review and meta-analysis of case-control studies","volume":"20","author":"Shah","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib132","first-page":"135","article-title":"Prevalence of primary eosinophilic colitis in patients with chronic diarrhea and diarrhea-predominant irritable bowel syndrome","volume":"87","author":"Carmona-S\u00e1nchez","year":"2022","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"10.1053\/j.gastro.2026.02.010_bib133","doi-asserted-by":"crossref","first-page":"13609","DOI":"10.3390\/ijms222413609","article-title":"Duodenal dysbiosis and relation to the efficacy of proton pump inhibitors in functional dyspepsia","volume":"22","author":"Wauters","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/srep34305","article-title":"Increased duodenal eosinophil degranulation in patients with functional dyspepsia: a prospective study","volume":"6","author":"Du","year":"2016","journal-title":"Sci Rep"},{"key":"10.1053\/j.gastro.2026.02.010_bib135","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1053\/j.gastro.2020.12.016","article-title":"Proton pump inhibitors reduce duodenal eosinophilia, mast cells, and permeability in patients with functional dyspepsia","volume":"160","author":"Wauters","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib136","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.cgh.2021.05.053","article-title":"Determination of biopsy yield that optimally detects eosinophilic gastritis and\/or duodenitis in a randomized trial of lirentelimab","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib137","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.cgh.2020.08.013","article-title":"Mast cell and eosinophil counts in gastric and duodenal biopsy specimens from patients with and without eosinophilic gastroenteritis","volume":"19","author":"Reed","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib138","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1007\/s10620-020-06689-2","article-title":"Functional dyspepsia and duodenal eosinophil count and degranulation: a multiethnic US Veteran cohort study","volume":"66","author":"J\u00e4rbrink-Sehgal","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib139","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5056\/jnm18176","article-title":"Degranulated eosinophils contain more fine nerve fibers in the duodenal mucosa of patients with functional dyspepsia","volume":"25","author":"Lee","year":"2019","journal-title":"J Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib140","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib141","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib142","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/j.1572-0241.2000.03177.x","article-title":"Serotonin: a mediator of the brain-gut connection","volume":"95","author":"Kim","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib143","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1053\/j.gastro.2011.12.041","article-title":"Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity","volume":"142","author":"Hoffman","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib144","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2982.2007.01059.x","article-title":"5-HT4 receptor agonists: similar but not the same","volume":"20","author":"De Maeyer","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib145","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","article-title":"A placebo-controlled trial of prucalopride for severe chronic constipation","volume":"358","author":"Camilleri","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib146","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2012.01983.x","article-title":"Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study","volume":"24","author":"Ke","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib147","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2125.2011.04088.x","article-title":"Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study","volume":"73","author":"Mendzelevski","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2026.02.010_bib148","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2036.2010.04455.x","article-title":"Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies","volume":"32","author":"Camilleri","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2009.01398.x","article-title":"Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study","volume":"21","author":"Camilleri","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib150","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2036.2008.03884.x","article-title":"Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study","volume":"29","author":"Quigley","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib151","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000070202","article-title":"Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial","volume":"67","author":"Coremans","year":"2003","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2026.02.010_bib152","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/j.1365-2036.2010.04456.x","article-title":"Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study","volume":"32","author":"Goldberg","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib153","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2982.2009.01378.x","article-title":"Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation","volume":"22","author":"Manini","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib154","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2982.2006.00865.x","article-title":"Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans","volume":"19","author":"Camilleri","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib155","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.physiol.62.1.535","article-title":"Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects","volume":"62","author":"Barrett","year":"2000","journal-title":"Annu Rev Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib156","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: iubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib157","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/17425255.2013.876410","article-title":"Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome","volume":"10","author":"Raschi","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1053\/j.gastro.2026.02.010_bib158","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1365-2036.2007.03320.x","article-title":"Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety","volume":"25","author":"Johanson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib159","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1572-0241.2007.01524.x","article-title":"Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation","volume":"103","author":"Johanson","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib160","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1365-2036.2008.03629.x","article-title":"Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation","volume":"27","author":"Johanson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib161","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2011.01668.x","article-title":"Efficacy and safety of oral lubiprostone in constipated patients with or without irritable bowel syndrome: a randomized, placebo-controlled and dose-finding study","volume":"23","author":"Fukudo","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib162","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2036.2011.04983.x","article-title":"Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation","volume":"35","author":"Chey","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib163","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1113\/jphysiol.2005.090399","article-title":"NHERF family and NHE3 regulation","volume":"567","author":"Donowitz","year":"2005","journal-title":"J Physiol"},{"key":"10.1053\/j.gastro.2026.02.010_bib164","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate","volume":"145","author":"Castro","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib165","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","article-title":"Two randomized trials of linaclotide for chronic constipation","volume":"365","author":"Lembo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib166","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","article-title":"Efficacy of linaclotide for patients with chronic constipation","volume":"138","author":"Lembo","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib167","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/apt.12123","article-title":"Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints","volume":"37","author":"Quigley","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib168","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/nmo.12089","article-title":"An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials","volume":"25","author":"Macdougall","year":"2013","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib169","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","article-title":"Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation","volume":"139","author":"Johnston","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17474124.2020.1722101","article-title":"Plecanatide for the treatment of constipation-predominant irritable bowel syndrome","volume":"14","author":"Miner","year":"2020","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib171","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ajg.2016.611","article-title":"A randomized phase iii clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation","volume":"112","author":"Miner","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib172","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2)","volume":"116","author":"Chey","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib173","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2011.261","article-title":"Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome","volume":"91","author":"Camilleri","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib174","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/nmo.12370","article-title":"The role of bile acids in functional GI disorders","volume":"26","author":"Appleby","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib175","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/ajg.2011.285","article-title":"Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation","volume":"106","author":"Wong","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib176","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/ajg.2011.162","article-title":"A randomized placebo-controlled phase IIb trial of A3309, a bile acid transporter inhibitor, for chronic idiopathic constipation","volume":"106","author":"Chey","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib177","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.14309\/ajg.0000000000002859","article-title":"Bile acid diarrhea is associated with an increased incidence of gastrointestinal cancers","volume":"119","author":"Ellegaard","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib178","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib179","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/SLA.0b013e3181deb4d0","article-title":"Overall mortality, incremental life expectancy, and cause of death at 25 years in the program on the surgical control of the hyperlipidemias","volume":"251","author":"Buchwald","year":"2010","journal-title":"Ann Surg"},{"key":"10.1053\/j.gastro.2026.02.010_bib180","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1007\/s10620-010-1229-y","article-title":"Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation","volume":"55","author":"Sloots","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib181","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/pme.12437","article-title":"A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain","volume":"15","author":"Cryer","year":"2014","journal-title":"Pain Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib182","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ajg.2015.106","article-title":"A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain","volume":"110","author":"Jamal","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"Suppl","key":"10.1053\/j.gastro.2026.02.010_bib183","doi-asserted-by":"crossref","first-page":"S538","DOI":"10.14309\/00000434-201410002-01819","article-title":"SP-333, a D-amino acid containing peptide agonist of guanylate cyclase-C, is a novel drug candidate for treatment of gastrointestinal disorders and diseases","volume":"109","author":"Palejwala","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"Suppl A","key":"10.1053\/j.gastro.2026.02.010_bib184","first-page":"71a","article-title":"Role of opioid ligands in the irritable bowel syndrome","volume":"13","author":"Corazziari","year":"1999","journal-title":"Can J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.02.010_bib186","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.02.010_bib187","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF01536922","article-title":"GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man","volume":"35","author":"Talley","year":"1990","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.02.010_bib188","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2036.1990.tb00458.x","article-title":"Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist","volume":"4","author":"Gore","year":"1990","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib189","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3109\/00365529509089790","article-title":"Ascending colon response to feeding: evidence for a 5-hydroxytryptamine-3 mechanism","volume":"30","author":"Scolapio","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib190","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2036.2000.00762.x","article-title":"Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers","volume":"14","author":"Houghton","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib191","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1046\/j.1365-2036.1998.00375.x","article-title":"Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome","volume":"12","author":"Delvaux","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib192","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.02.010_bib193","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/apt.17426","article-title":"Randomised, placebo-controlled trial and meta-analysis show benefit of ondansetron for irritable bowel syndrome with diarrhoea: the TRITON trial","volume":"57","author":"Gunn","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.02.010_bib194","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000150632","article-title":"A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome","volume":"77","author":"Matsueda","year":"2008","journal-title":"Digestion"},{"key":"10.1053\/j.gastro.2026.02.010_bib195","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/00365520802240255","article-title":"A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome","volume":"43","author":"Matsueda","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib196","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cgh.2013.11.024","article-title":"Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea","volume":"12","author":"Fukudo","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib197","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cgh.2013.12.025","article-title":"Ramosetron in irritable bowel syndrome with diarrhea: new hope or the same old story?","volume":"12","author":"Grover","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.02.010_bib198","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CEG.S32721","article-title":"Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome","volume":"6","author":"Chiba","year":"2013","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1053\/j.gastro.2026.02.010_bib199","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1365-2982.2011.01771.x","article-title":"Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine","volume":"23","author":"Lee","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1053\/j.gastro.2026.02.010_bib200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/gutjnl-2018-318160","article-title":"Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis","volume":"69","author":"Black","year":"2020","journal-title":"Gut"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526001411?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508526001411?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:21:28Z","timestamp":1786350088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508526001411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":200,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0016508526001411"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.02.010","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Disorders of Gut\u2013Brain Interaction","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}]}}